Belize - I've given my opinion several times regarding your questions. I've said it many times with the reasons why it's +5B BO. I've presented everything that I've read, and what makes sense to me - based on deductive reasoning. You've read Marth's comments, yet seem to have no memory of their business model. If MDT or J&J want to jump into, or get further ahead they will need to acquire patents that lead to new products, new market segments and generate new revenue. AKA - buying growth. They're not going to get ahead of ISRG with just HUGO. Why would MDT let TMDI reap all of the new revenue, when it's right in front of them and available? Or worse, let J&J in the door? I don't know what else your fishing for.
Meeting the second condition is not paying off the loan early. It's meeting one of the 3 ways supposedly when it may be paid. And again, that's one of my points that MDT is posturing to BO TMDI otherwise there would be an early payoff provision in the loan - and I don't see one.
And IMO Mc isn't permitting a "gag order." And, while you ask a good question, there are times when details can not be disclosed that would reveal all of the reasons we're here under these circumstances. If you were MDT, wouldn't you keep a lid on as many details as possible? If you were Mc would you disclose them anyway? I think not.
Within the realm of possibility is that MDT comes up with additional - new milestones that take the redacted information into the 2023 deadline. Which may again create the same circumstances for public announcements/communication. I'm not making any excuses for anyone, but Mc better make MDT pay more for the "extensions" or if MDT desires to license additional IP. Otherwise it would appear on the surface that he's not performing his required fiduciary duties. IMO.
Why? B/c a case can be made "without knowing all of the details" that working on MDT projects monopolizes Cambridge assets and causes further delays to finishing ENOS. There must be payment that has the requisite effect of substantial added value to the company's net worth for creating delays and exposing/subjecting TMDI to potentially adverse competitor products and market conditions. That part of the negotiation is on both Mc and the BOD.
And again, MDT is only licensing 33% of Titan's IP. Once that loan is paid, Titan can sell to whomever they want. If MDT can see what it's worth, then I can only conclude other RAS med device companies are just as smart and resourceful. So there are more opportunities than just MDT - if they're so inclined to not offer a competitive BO. Remember, there are 10's of thousands of former and present investors and countless investment funds that have owned ISRG. I'm sure they will all capitulate and accept a low-ball BO. Pfffft. They want another bite at the apple. And this investment experience will be accelerated from FOMO as everyone knows the ISRG path from pre-FDA to selling daVinci. IMO. Don't you think ISRG will make a bid, just to make sure MDT pays the requisite price to play? Their going to make it hurt more than just a little. And the best way is to make it really damn expensive.
And in response to your MP is better - what about 2 ENOS? Use them separately or together. Better than an MP? Perhaps.
We're all waiting anxiously.
Good luck to all. Regards,BK.
